These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35869411)

  • 1. Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves?
    Li S; Zhang Y
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):595-600. PubMed ID: 35869411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?
    Aimo A; Giugliano RP; De Caterina R
    Circulation; 2018 Sep; 138(13):1356-1365. PubMed ID: 30354416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor Xa Inhibitors for Patients after Mechanical Heart Valve Replacement?
    Gerfer S; Grandoch M; Wahlers TCW; Kuhn EW
    Thorac Cardiovasc Surg; 2023 Apr; 71(3):189-194. PubMed ID: 34894638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
    Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
    Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
    Lee A; Rajaratnam R
    Heart Lung Circ; 2014 Jan; 23(1):2-9. PubMed ID: 24183214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
    Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
    Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of direct and indirect factor Xa inhibitors.
    Rupprecht HJ; Blank R
    Drugs; 2010 Nov; 70(16):2153-70. PubMed ID: 20964458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
    Palareti G
    Semin Hematol; 2014 Apr; 51(2):102-11. PubMed ID: 24861794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
    Deedwania P; Huang GW
    Rev Cardiovasc Med; 2012; 13(2-3):e89-104. PubMed ID: 23160166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].
    Korin J
    Medicina (B Aires); 2012; 72(5):419-24. PubMed ID: 23089119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
    Lee YK; Player MR
    Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Bleker SM; Brekelmans MPA; Eerenberg ES; Cohen AT; Middeldorp S; Raskob G; Büller HR
    Thromb Haemost; 2017 Oct; 117(10):1944-1951. PubMed ID: 28816341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.